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ABSTRACT 
 
Frequent BRAF V600E mutation  
in keratocystic odontogenic tumor 
 
 
Eunae Sandra Cho 
 
Department of Dentistry 
The Graduate School, Yonsei University 
(Directed by Professor Jong Hoon Choi) 
 
Keratocystic odontogenic tumor (KCOT) is a benign intraosseous odontogenic 
epithelial tumor in the jaw, characterized as an odontogenic cyst, odontogenic 
keratocyst, in the past. In 2005, the World Health Association working group 
vi 
reclassified the cyst as a benign tumor for several clinical and molecular genetic 
reasons.  
Clinically, KCOT shows aggressive growth patterns and high recurrence rates 
which is relatively similar to odontogenic tumors rather than odontogenic cysts. 
Molecular genetic features present in KCOT support its neoplastic behavior as well, 
such as proliferative markers and tumor suppressor gene mutations/loss of 
heterozygosity. Although PTCH gene mutation was considered to be critical in 
KCOT pathogenesis due to its close association in syndrome related lesions, there 
are needs in identifying other oncogenic mutations, especially in sporadic KCOT. 
BRAF V600E mutation has been identified in odontogenic tumors, 
representatively ameloblastoma. It is an oncogenic driver mutation which activates 
the mitogen-activated protein kinase (MAPK) pathway and has commercial target 
inhibitors, such as vemurafenib and dabrafenib.  
In this study, frequent BRAF V600E mutation was identified in KCOT by gene 
sequencing. The results are as follows. 
1. BRAF V600E mutations were identified for the first time in 63.2% of KCOT 
and 28.6% of OOC by sanger sequencing in formalin fixed paraffin embedded 
tissue samples with/without microdissection.  
vii 
2. There was no statistically significant difference between KCOT mutation status 
and clinical information such as age, sex, location, recurrence and multiple 
lesions.  
3. The gold standard to identify BRAF V600E mutation in KCOT is gene 
sequencing rather than immunohistochemistry. 
4. Microdissection is useful in validating mutations in cystic tumors or inflamed 
lesions.  
The results support KCOT as a tumor and relates its pathogenesis to BRAF V600E 
mutation and the MAPK pathway. BRAF target inhibitors are expected to be an 
effective and non-invasive future therapeutics for KCOT in the future. 
 
 
 
 
 
Key words : Keratocystic odontogenic tumor, BRAF V600E, mitogen-activated 
protein kinase pathway, vemurafenib, dabrafenib 
１ 
Frequent BRAF V600E mutation  
in keratocystic odontogenic tumor 
 
Eunae Sandra Cho 
 
Department of Dentistry 
The Graduate School, Yonsei University 
(Directed by Professor Jong Hoon Choi) 
 
 
I. Introduction 
Keratocystic odontogenic tumor (KCOT) is a benign intraosseous odontogenic 
epithelial tumor in the jaw. KCOT has been long been characterized as an 
odontogenic cyst, specifically an odontogenic keratocyst. In 2005, the World Health 
Association working group reclassified the cyst as a benign tumor for several 
２ 
clinical and molecular genetic reasons (Barnes, Eveson et al. 2005). Aggressive 
growth patterns and high recurrence rates raised an issue regarding nomenclature 
as far back as the 1960s (Toller 1967). The recurrence rate in studies over the last 
two decades varies from 15-58%, depending on the treatment status (Myoung, 
Hong et al. 2001, Zhao, Wei et al. 2002, Finkelstein, Hellstein et al. 2013, Sanchez-
Burgos, Gonzalez-Martin-Moro et al. 2014). Compared to KCOT, the recurrence 
rate of the benign but aggressive ameloblastoma is 8-38% (Reichart, Philipsen et al. 
1995, Antonoglou and Sandor 2015) while that of the histologically similar 
orthokeratinized odontogenic cyst (OOC) is 0-6% (Li, Kitano et al. 1998, Dong, 
Pan et al. 2010).  
Recently, molecular genetic features present in various tumors have been found 
in KCOTs as well. Proliferative markers proliferating cell nuclear antigen and 
Ki67 were expressed higher than in typical odontogenic cysts although this does 
not directly prove KCOT is a tumor (Li, Browne et al. 1994, Li, Browne et al. 
1995, Piattelli, Fioroni et al. 1998). Tumor suppressor genes (e.g. p53, p16, MCC, 
FHIT and PTCH) demonstrated mutations or loss of heterozygosity in several 
cases, supporting the neoplastic biologic behavior of KCOT (Lombardi, Odell et 
al. 1995, Li, Browne et al. 1996, Agaram, Collins et al. 2004, Malcic, Jukic et al. 
2008).  
３ 
Among these, the PTCH gene is supposed to be important in KCOT pathogenesis. 
Mutation in the PTCH gene, a part of the Sonic Hedgehog (SHH) pathway, was first 
detected in patients with nevoid basal cell carcinoma syndrome (NBCCS), then 
identified in sporadic KCOTs (Lench, Telford et al. 1997, Barreto, Gomez et al. 
2000, Gu, Zhao et al. 2006). Aberrant activation of the SHH pathway in both 
sporadic and NBCCS related KCOT has been suggested by studies of SHH-related 
gene mutation as well as of immunoprotein expression profiles (Ohki, Kumamoto 
et al. 2004, Vered, Peleg et al. 2009). Compared with PTCH gene mutation in 
NBCCS, sporadic KCOT has a lower mutation frequency, different distribution 
pattern of mutation domains, and may need a more complicated ‘two hit’ somatic 
mutation (Levanat, Gorlin et al. 1996, Vered, Peleg et al. 2009, Mendes, Carvalho 
et al. 2010, Guo, Zhang et al. 2013). Therefore, other gene mutations in sporadic 
KCOT have drawn attention despite the clear role of the PTCH gene and SHH 
pathway in NBCCS. 
BRAF mutation, specifically the BRAF V600E mutation, has been identified in 
odontogenic tumors such as ameloblastoma and ameloblastic-like lesions (Brown, 
Rolland et al. 2014, Kurppa, Caton et al. 2014, Sweeney, McClary et al. 2014, 
Brunner, Bihl et al. 2015). It was originally identified in malignant tumors such as 
malignant melanoma, colorectal cancer and ovarian cancers (Davies, Bignell et al. 
４ 
2002). Later, it was recognized in benign melanocytic nevus and suspected as a 
driver mutation beginning with its benign status and continuing throughout 
malignant alterations (Pollock, Harper et al. 2003, Yazdi, Palmedo et al. 2003, Shain, 
Yeh et al. 2015).  
The purpose of this study was to validate BRAF V600E mutations in KCOT 
using formalin fixed paraffin embedded (FFPE) tissue samples and to identify a 
molecular pathogenetic target for non-invasive therapeutics.    
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II. Material and methods 
1. Samples 
FFPE tissue samples from 39 cases of KCOT (38 patients), 7 cases of OOC, 4 
cases of ameloblastoma, and 2 cases of pyogenic granuloma were obtained from 
the Department of Oral Pathology at Yonsei University. Ameloblastoma samples 
were included to re-confirm previous reports and pyogenic granuloma samples 
consisting of nonspecific inflammatory granulation tissue were selected as a 
negative control for gene sequencing. If there were multiple block sections in a 
single lesion, the preferred conditions were excised, non-decalcified, non-inflamed, 
higher tumor fraction sections over incised, decalcified, inflamed and lower tumor 
fraction. All tissue samples, sectioned and stained with hematoxylin-eosin (H-E), 
were reviewed and diagnosed by oral pathologists E. S. C. and J. I. Y. Clinical 
information such as age, sex, location, recurrence status, multiple lesions status, and 
clinical features suggestive of NBCCS were recorded retrospectively.   
 
2. Tumor fraction analysis and microdissection  
Tumor fraction was calculated in all the samples by H-E slide examination and 
ImageJ (1.50i, National Institutes of Health, USA) (Figure 1A). Samples with tumor 
６ 
fractions less than 20% were manually microdissected until the tumor fraction 
exceeded 50% (Figure 1B). Microdissection of the tumor was done on a wet glass 
slide of sectioned unstained paraffin block with a thickness of 10㎛. Areas of 
heavily inflamed tissue were avoided during microdissection. 
 
3. Genomic DNA isolation and PCR 
Genomic DNA was isolated from FFPE sections (thickness 5~10㎛) by QIAamp 
DNA FFPE Tissue Kit (QIAGEN, cat. No. 56404) following the manufacturer’s 
instruction manual. Paraffin was removed with xylene and the remaining tissue was 
bound with 100% ethanol. The contents were lysed with proteinase using lysis 
buffer at 56°C, 1 hour and 90°C, over 1 hour on heat block. DNA precipitation and 
quantification (50ng/㎕) was done. PCR using ACCUPOWER Pfu premix (50㎕ 
reaction, Bioneer) was done for 35 cycles (94°C for 30 s, 58°C for 30 s and 72°C 
for 60 s). The primer sequence for BRAF (600) was forward 5’-
TGCTTGCTCTGATAGGAAAATG-3’ and reverse 5’-
CCACAAAATGGATCCAGACA-3’ as previously reported (Sweeney, McClary et 
al. 2014). The PCR products were verified through gel electrophoresis (1.5% agrose 
gel, expected product size: 173bp) and purified.   
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Figure 1. Identification process of BRAF V600E mutation in keratocystic 
odontogenic tumor (KCOT) 
A. Gene sequencing with or without microdissection, rather than 
immunohistochemistry, is the gold standard to identify BRAF V600E 
mutation in KCOT.  
B. Microdissection of tumor epithelium in KCOT (hematoxylin-eosin, x10, 
scale bar = 500 ㎛).  
B 
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4. Sanger sequencing 
Sanger sequencing (Macrogen) was done and review of the sequence was 
performed by manual examination. The sample was defined as a mutant if there 
was a definite sequencing peak of BRAF c.1799 T>A. Samples with indefinite 
sequencing peaks of BRAF c.1799 T>A mutation were clarified by taq-PCR TA 
cloning (T vector, Real Biotech Corp.) and blue white screening.     
 
5. Immunohistochemistry 
Immunohistochemistry was performed on 3㎛ sectioned FFPE sections with 
BRAF V600E mutation specific antibody at ASAN medical center (Ventana, clone 
VE1, 12㎍/ml and Ventana BenchMark XT immunostainer) and at Yonsei 
University, Department of Oral Pathology (NewEast biosciences, 1:100 and manual 
staining). A BRAF V600E mutated human colorectal cancer specimen was used as 
positive control during automated staining.   
 
6. Statistics 
Chi-square test and Fisher’s exact test were performed on the association of 
mutation and clinical information. Recurrence-free survival was determined by the 
１０ 
aplan-Meier method using log-rank test. Analysis was done with SPSS statistics 
21.0 (SPSS Inc, Chicago, IL, USA). The level of statistical significance was set at 
p < 0.05.  
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III. Results 
1. Frequent BRAF V600E mutation in KCOT by gene sequencing 
We collected 39 cases of KCOT (38 patients), 7 cases of OOC, 4 cases of 
ameloblastoma, and 2 cases of pyogenic granuloma. 2 samples of recurrent multiple 
KCOT were collected from the same patient and only the primary lesion was 
included in statistical analysis.  
BRAF V600E mutations were identified in the KCOT, OOC and ameloblastoma 
samples (Figure 2 and 3). Mutation ratio was 63.2% in KCOT, 28.6% in OOC 
(Table 1), 50% in ameloblastoma and 0% in pyogenic granuloma. The 2 recurrent 
multiple KCOT lesion samples from the same patient were both BRAF wild type. 
 
2. Analysis of BRAF V600E mutation status and clinical characteristics 
association  
There was no statistically significant difference between KCOT mutation status 
and clinical information such as age, sex, location, recurrence and multiple lesions 
(Table 2). In the KCOT samples, average patient age at sample collection was 30 
years old, and the male to female ratio about 3:2. 58% of the samples were from 
the mandible, while the rest were from the maxilla. 50% were from the right side and  
１２ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Frequent BRAF V600E mutation (63.2%) was identified in 
keratocystic odontogenic tumor (KCOT) by sanger sequencing.   
A. V600E mutant KCOT samples with T>A at nucleotide 1799. 
B. Wild type KCOT samples with a single T peak at nucleotide 1799. 
A 
B 
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   A 
B 
C 
Figure 3. Gene sequencing results of orthokeratinized odontogenic cyst 
(OOC), ameloblastoma, and pyogenic granuloma. 
A. 2 of the 7 OOC samples (28.6%) were BRAF V600E mutants. 
B. 50% of the ameloblastoma samples were BRAF V600E mutants which 
confirmed the previous reports (Left: mutant, Right: wild type).  
C. Pyogenic granuloma samples were selected as negative control and were 
all BRAF wild types. 
１４ 
Pathologic 
diagnosis 
Patients (n) V600E mut (n) BRAF wt (n) Mutation (%) 
KCOT 38 24 14 63.2 
OOC 7 2 2 28.6 
 
Table 1. BRAF V600E mutation frequency in keratocystic odontogenic tumor 
(KCOT) and orthokeratinized odontogenic cyst (OOC). (mut: mutant, wt: 
wild type) 
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Mutation status 
 
Clinical characteristics  
Total 
(n=38) 
V600E mut 
(n=24) 
BRAF wt 
(n=14) 
p 
value 
Age at sample collection (years) 30±14 32±14 27±13 0.242 
Age at initial diagnosis (years) 28±15 31±15 24±13 0.157 
Sex; male  63% (24) 67% (16) 57% (8) 0.403 
Sample location; maxilla  42% (16) 33% (8) 57% (8) 0.137 
Sample location; mandible  58% (22) 67% (16) 43% (6) 0.137 
Pt with recurrence experience  63% (24) 58% (14) 71% (10) 0.326 
Pt with multiple lesions 34% (13) 25% (6) 50% (7) 0.113 
Pt : patient(s) 
 
Table 2. Clinical characteristics of BRAF V600E mutant (mut) and wild type 
(wt) keratocystic odontogenic tumor.  
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79% were from the posterior side.  
63% of the total KCOT patients had experienced recurrent lesions during the 
follow up period, while all the OOC patients were free of recurrence. Recurrence 
free survival showed no statistically significant difference (p value = 0.479) 
between mutants and wild types (Figure 4). 
34% of the patients had multiple lesions. Although most of the patients had 
definitive sporadic lesions, 2 of the multiple KCOT patients fit two major criteria 
of NBCCS such as basal cell carcinoma under 30 years and multiple palmar pitting. 
A patient with a single KCOT lesion occurred with one minor criterion 
(medulloblastoma) and was suspicious of NBCCS. Within the 3 patients who 
showed NBCCS-related characteristics, 2 samples with multiple KCOTs matching 
major criteria were mutants and a sample with single KCOT matching minor criteria 
was wild type (Neville, Allen et al. 2016).  
All 3 samples with pre- or post-ameloblastoma occurrence and/or focal 
ameloblastic change were mutants and exhibited recurrence during the follow-up 
period. 2 samples with focal ameloblastic change in the KCOT had a history of 
primary or recurrent ameloblastoma and yet another typical sample later recurred 
into a KCOT with ameloblastic change during follow-up. 
１７ 
 
 
  
Figure 4. 5 year follow up recurrence free survival (in days) for BRAF 
V600E mutant (mut) and wild type (wt) keratocystic odontogenic tumor 
(KCOT) patients using Kaplan-Meier method.  
Patients with recurrent event(s) within 5 years from the first treatment 
regardless of follow up period, or patients without recurrent event(s) fulfilling 
the 5 year follow up were included for analysis (n=29).  
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3. Negative BRAF immunohistochemistry results in KCOT 
Immunohistochemistry results were negative in all of the KCOT samples (Figure 
5). Colorectal cancer used as a positive control stained strong, diffusely staining at 
the tumor cell cytoplasm, verifying the staining process. Ameloblastoma showed a 
weak stain on the tumor cells but staining results did not fully correlate with the 
genetic status.    
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  A B 
C D 
Figure 5. Negative BRAF immunohistochemistry results (VE1 clone) 
Both keratocystic odontogenic tumor (KCOT) mutant sample (A, x100) and 
KCOT wild type sample (B, x100) did not show positive staining in the tumor 
cells. A colorectal cancer sample with BRAF V600E mutation (C, x100) was 
used as positive control. Ameloblastoma mutant sample showed a diffuse weak 
cytoplasmic staining in the tumor cells and negative staining results in the 
stromal cells (D, x100) (scale bar = 100 ㎛). 
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IV. Discussion 
BRAF V600E mutations were identified for the first time in KCOT as well as 
OOC. BRAF mutations are known to activate the mitogen-activated protein kinase 
(MAPK) pathway, resulting in abnormal cell proliferation and survival. Among 
BRAF mutations, V600E is the most common type, with valine substituted for 
glutamic acid at codon 600 in exon 15 (Davies, Bignell et al. 2002, Hertzman 
Johansson and Egyhazi Brage 2014). KCOT showed a high frequency of mutants, 
similar or slightly higher than the mutation rate previously reported in 
ameloblastoma (46-63%) (Brown, Rolland et al. 2014, Kurppa, Caton et al. 2014, 
Sweeney, McClary et al. 2014), while OOC showed a much lower frequency of 
mutants. Although OOC was once treated as an orthokeratinized variant of KCOT, 
it has recently come to be thought of as a distinct type of odontogenic cyst while 
KCOT has been reclassified as a neoplasm (Li, Kitano et al. 1998, Dong, Pan et al. 
2010). Interestingly, all the samples with pre- or post-ameloblastoma occurrence 
and/or focal ameloblastic change were mutants. This suggests that KCOT and 
ameloblastoma share certain parts of their genetic pathogenesis and supports KCOT 
as a tumor. BRAF mutation was identified in both sporadic and syndrome 
associated KCOTs. Samples in this study with definite diagnostic criteria of 
NBCCS were all mutants. Although genetic confirmation of NBCCS was not 
２１ 
medically concluded in the patients, BRAF mutation was suspected to play a role 
in syndrome-associated KCOT pathogenesis.  
A previous study has failed to confirm BRAF mutation in KCOT in 1 case 
(Brunner, Bihl et al. 2015). Besides the insufficient case number of the study, 
identifying BRAF mutations in FFPE tissues of KCOT requires an attentive 
approach. Cystic tumors have a relatively low tumor fraction compared to solid 
tumors. Furthermore, cystic odontogenic lesions with a history of marsupialization 
or decompression accompany dense inflammatory cell infiltration and increased 
stroma. Dense nonspecific inflammation decreases tumor fraction and may mask 
samples as wild type rather than mutant. Microdissection was introduced in this 
study to increase tumor fraction and reveal mutants hidden behind inflammation 
and thick stromal tissue. This method may be useful in validating mutations in 
cystic tumors or inflamed lesions.  
Immunohistochemistry was done multiple times, both by automatically and 
manually, but never revealed positive protein expression in the cyst epithelial 
tumor cells. Colorectal cancer, a positive control, expressed definite positive 
cytoplasmic staining, which indicated that the staining process was technically 
acceptable. As a point mutation, BRAF V600E may exhibit protein expression too 
low to detect with immunohistochemistry (Capper, Preusser et al. 2011); the gold 
２２ 
standard in validating the mutation is gene sequencing with or without 
microdissection (Figure 6). 
Correlation between BRAF V600E mutant status and clinical information could 
not be proven in KCOT. Ameloblastoma studies report correlations between BRAF 
V600E mutant status and age, location, and recurrence-free survival, (Brown, 
Rolland et al. 2014, Sweeney, McClary et al. 2014, Fregnani, da Cruz Perez et al. 
2016), results not found in this study of KCOT. Because BRAF wild type tumors 
likely bear other oncogenic mutations which may influence the mentioned factors, 
it is understandable that studies would yield different results with respect to these 
correlations. Further research is needed to validate the complete oncogenic 
mutation profile in KCOT. 
In KCOT, therapeutics additional to surgery may be an effective alternative due 
to various complications in surgery and its high recurrence rate. Brannon suggested 
that the high recurrence rate of KCOT was due to epithelial remnants adjacent to 
the former lesion, incomplete removal of the friable epithelial lining, and satellite 
cysts (Brannon 1977). Traditional treatment options are enucleation, excision, 
ostectomy and en bloc resection (Sharif, Oliver et al. 2015). KCOT most frequently 
occurs in the second and third decade and often is multilocular (Brannon 1977, 
Myoung, Hong et al. 2001), so surgical treatment planning with an esthetic focus   
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  A Wild type V600E mutant 
B 
Weak V600E mutant signal, 
20%> tumor fraction Confirmed by microdissection 
C Weak V600E mutant signal Confirmed by TA cloning 
Figure 6. Methods to increase accuracy of gene sequencing results in 
keratocystic odontogenic tumor. 
A. General PCR amplification and sanger sequencing 
B. Microdissection in samples with less than 20% tumor fraction resulted in a 
stronger A nucleotide signal, confirming mutation. 
C. Samples with weak V600E mutation signals were confirmed with TA 
cloning. 
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may encounter limitations. 
Inhibitors targeting BRAF mutations and the MAPK pathway may play a 
potential role in KCOT with BRAF mutations. BRAF inhibitors vemurafenib and 
dabrafenib are United States Food and Drug Administration (FDA) approved drugs 
for metastatic melanoma (Chapman, Hauschild et al. 2011, Menzies and Long 
2014). Drug resistance is a problem when treating malignancies with BRAF 
inhibitors because of constant additional genetic alterations which make full 
recovery difficult (Hertzman Johansson and Egyhazi Brage 2014). Effective 
therapeutic results are expected in benign tumors due to their simpler genetic 
mutation profile (Yazdi, Palmedo et al. 2003, Michaloglou, Vredeveld et al. 2008, 
Shain, Yeh et al. 2015). KCOT recurrence is frequent because of its satellite cysts 
and cyst epithelium remnant after surgery. Pre- or post-operative use of BRAF 
inhibitors may control the growth of the tumor remnants and potentially constrain 
the aggressive biological behavior, decreasing the total range of surgery and 
recurrence rate.     
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VI. Supplementary tables 
No Age Sex Location Treatment 
Recurrence 
status 
No. of 
lesions 
BRAF 
status 
TF 
(%) 
other 
Keratocystic odontogenic tumor (KCOT) 
1 37 f 
Right 
posterior 
mandible 
enucleation 
Primary    
without  
recurrence 
single V600E 30  
2 54 f 
Left 
posterior 
maxilla 
enucleation 
Primary 
without 
recurrence 
single V600E 20  
3 33 m 
Left 
posterior 
maxilla 
enucleation 
3rd in 3 
recurrences 
single V600E 20  
4 31 m 
Left 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
single V600E 50  
5 32 m 
Left 
posterior 
mandible 
enucleation 
2nd in 2 
recurrences 
single V600E 50  
6 20 m 
Left 
posterior 
maxilla 
enucleation 
Primary 
without 
recurrence 
single wt 20  
7 38 m 
Right 
posterior 
maxilla 
enucleation 
Primary 
without 
recurrence 
single V600E 10>  
8 50 m 
Right 
anterior 
mandible 
enucleation 
1st in 1 
recurrence 
single wt 20  
9 35 m 
Left 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
single V600E 20  
10 22 f 
Left 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
single V600E 20  
11 59 m 
Left 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
single V600E 10  
12 34 m 
Right 
posterior 
mandible 
enucleation 
1st in 1 
recurrence 
single wt 60  
13 29 f 
Left 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
single wt 30  
14 52 f 
Left 
posterior 
mandible 
curettage 
Primary in 1 
recurrence 
single wt 20  
15 10 m 
Right 
posterior 
maxilla 
enucleation 
Primary in 1 
recurrence 
single wt 30 medulloblastoma 
16 20 m 
Left 
posterior 
mandible 
enucleation 
Primary in 1 
recurrence 
single V600E 10  
17 36 m Right enucleation Primary in 1 single wt 30  
３３ 
posterior 
mandible 
recurrence 
18 12 f 
Right 
maxilla 
enucleation 
Primary in 2 
recurrences 
single V600E 10>  
19 69 m 
Right 
anterior 
mandible 
enucleation 
Primary in 2 
recurrences 
single V600E 30  
20 31 m 
Left 
posterior 
mandible 
enucleation 
Primary in 2 
recurrences 
single V600E 10  
21 33 m 
Right 
anterior 
maxilla 
enucleation 
Primary in 2 
recurrences 
single V600E 20  
22 33 m 
Left 
posterior 
mandible 
enucleation 
Primary in 2 
recurrences 
single V600E 50  
23 49 m 
Right 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
single V600E 10>  
24 15 f 
Right 
posterior 
maxilla 
enucleation 
Primary 
without 
recurrence 
multiple wt 10  
25 32 f 
Left 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
multiple V600E 40 
palmar pitting, 
epidermal cyst 
26 13 m 
Left 
posterior 
maxilla 
enucleation 
Primary in 1 
recurrence 
multiple V600E 30  
27 16 f 
Right 
posterior 
mandible 
incision 
Primary 
without 
recurrence 
multiple V600E 10>  
28 23 m 
Right 
posterior 
maxilla 
enucleation 
2nd in 2 
recurrences 
multiple wt 10  
29 13 m 
Left 
posterior 
maxilla 
enucleation 
Primary in 2 
recurrences 
multiple wt 10  
30 15 m 
Right 
anterior 
maxilla 
enucleation 
2nd in 2 
recurrences 
multiple V600E 10 
palm basal cell 
carcinoma 
31 20 f 
Right 
posterior 
maxilla 
enucleation Primary* multiple V600E 40  
32 28 f 
Left 
maxilla 
enucleation 
Primary in 2 
recurrences 
multiple wt 30 
Same person 
with no.33 
33 33 f 
Right 
posterior 
mandible 
enucleation 
2nd in 2 
recurrences 
multiple wt 20 
Same person 
with no.32 
34 14 f 
Right 
anterior 
maxilla 
enucleation 
1st in 1 
recurrence 
multiple wt 30  
35 34 f 
Left 
posterior 
maxilla 
enucleation Primary* multiple V600E 30  
36 15 m 
Left 
posterior 
mandible 
enucleation 
Primary 
without 
recurrence 
multiple wt 10  
37 32 f Right enucleation Primary* multiple wt 10  
３４ 
posterior 
maxilla 
38 33 m 
Right 
posterior 
mandible 
enucleation 
2nd in 2 
recurrences 
single V600E 20 
Uncystic 
ameloblastoma 
arised before 
KCOT 
39 18 m 
Right 
anterior 
mandible 
enucleation 
1st in 1 
recurrence 
single V600E 60 
Recurred as 
ameloblastoma 
Orthokeratinized odontogenic cyst (OOC) 
40 32 m 
Right 
posterior 
mandible 
enucleation Primary single V600E 20  
41 17 f 
Right 
posterior 
mandible 
enucleation Primary single wt 50  
42 56 f 
Right 
posterior 
mandible 
enucleation Primary single wt 20  
43 16 f 
Left 
posterior 
maxilla 
enucleation Primary single wt 60  
44 27 f 
Right 
posterior 
mandible 
enucleation Primary single wt 20  
45 34 m 
Left 
posterior 
mandible 
enucleation Primary single wt 40  
46 32 m 
Left 
posterior 
mandible 
enucleation Primary single V600E 50  
Primary*: Primary lesion in multiple KCOT; Current location is not associated with recurrence but 
other locations may have had recurrent events. 
TF: Tumor (cystic epithelium) fraction, V600E: BRAF V600E mutant, wt: wild type 
 
 
 
Supplementary table 1. Clinical information and BRAF mutation status of 
keratocystic odontogenic tumor (KCOT) and orthokeratinized odontogenic 
cyst (OOC) patients 
 
 
 
 
３５ 
No Diagnosis Age Sex Location Treatment 
BRAF 
status 
47 
Ameloblastoma 
 
40 m Left posterior mandible excision wt 
48 58 m Left anterior mandible excision wt 
49 26 f Right posterior mandible excision V600E 
50 22 m Right mandible biopsy V600E 
51 Pyogenic 
granuloma 
51 f Buccal mucosa excision wt 
52 37 f Left mandible excision wt 
V600E: BRAF V600E mutant, wt: wild type 
 
 
Supplementary table 2. Clinical information and BRAF mutation status of 
ameloblastoma and pyogenic granuloma patients 
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ABSTRACT (IN KOREAN) 
 
각화낭성치성종양에서  
높은 빈도로 발생하는 BRAF V600E 유전자 변이 
 
 
<지도교수 최종훈> 
연세대학교 대학원 치의학과 
조은애산드라 
 
각화낭성치성종양은 악골의 양성 골내 치성 상피 종양으로 과거 치성
각화낭이라는 명칭의 치성낭으로 분류되었다. 세계보건기구는 2005년
에 각화낭성치성종양을 낭에서 종양으로 재정의를 하였다. 
임상적으로 각화낭성치성종양은 공격적인 성장 양상과 상대적으로 높
은 재발율을 보이는데, 이는 치성낭보다 치성종양의 특성에 가깝다. 분
３７ 
자유전학적인 관점에서도 종양의 특성을 보이는데, 증식 관련 표지자와 
종양억제유전자변이/이형접합성상실 등이 그 예이다. 이중 PTCH 유전
자 변이가 가장 중요하게 여겨졌으나 기저세포모반증후군과 관련된 병
소와 달리 산발적으로 발생하는 병소에서는 낮은 변이 비율 등 근거가 
상대적으로 뚜렷하지 않아 다른 종양성 유전자 변이를 발견할 필요성이 
있다.    
최근에 BRAF V600E 유전자 변이는 법랑모세포종을 비롯한 치성종
양에서 발견이 되었다. 이는 종양 유발 유전자변이로 mitogen-activated 
protein kinase (MAPK) 경로를 활성화하며 베무라페닙과 다브라페닙과 같
은 상용화된 억제제 약물이 있다.  
이 연구에서는 각화낭성치성종양에서 높은 빈도로 BRAF V600E 유
전자 변이가 발생한다는 것을 유전자 시퀀싱을 통해 관찰하였다. 연구 
결과는 다음과 같다.  
1. 포르말린 고정 조직에 유전자 시퀀싱을 하여 최초로 63.2%의 각화
낭성치성종양과 28.6%의 진성각화치성낭에서 BRAF V600E 유전자 
변이를 관찰되었다.  
３８ 
2. 각화낭성치성종양의 BRAF 유전자 변이 여부와 임상적 양상 (연령, 
성별, 발병 위치, 재발 여부 및 다발성 병소 여부 등)은 통계학적으
로 유의한 연관성을 보이지 않았다.  
3. 각화낭성치성종양에서 BRAF V600E를 확인하기에 가장 적합한 방법
은 면역조직화학염색보다 유전자 시퀀싱이다.  
4. 낭성 종양 또는 염증이 심한 조직에서는 현미해부를 통해 유전자 
변이 여부를 더 정확하게 확인 할 수 있다. 
이러한 연구 결과들은 각화낭성치성종양이 종양임을 다시 한번 확인 시
켜주며 BRAF V600E 유전자 변이 및 MAPK 경로와 연관된 병인을 가지
고 있음을 보여준다. 이는 각화낭성치성종양의 치료로 표적 억제제를 
이용한 비침습적 치료의 가능성을 제시하여 준다.   
  
 
 
핵심어: 각화낭성치성종양, BRAF V600E, mitogen-activated protein kinase 
pathway, 베무라페닙, 다브라페닙 
